Recombinant
RabMAb

Recombinant Anti-IL-1 beta antibody [EPR21086] - BSA and Azide free (ab229696)

Overview

  • Product name

    Anti-IL-1 beta antibody [EPR21086] - BSA and Azide free
    See all IL-1 beta primary antibodies
  • Description

    Rabbit monoclonal [EPR21086] to IL-1 beta - BSA and Azide free
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IPmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human IL-1 beta aa 100 to the C-terminus. The exact sequence is proprietary.
    Database link: P01584

  • Positive control

    • WB: LPS treated THP-1 whole cell lysate.
  • General notes

    Ab229696 is the carrier-free version of ab216995. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    ab229696 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab229696 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 35, 29, 17 kDa (predicted molecular weight: 30 kDa).
IP Use at an assay dependent concentration.

Target

  • Function

    Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.
  • Tissue specificity

    Expressed in activated monocytes/macrophages (at protein level).
  • Sequence similarities

    Belongs to the IL-1 family.
  • Post-translational
    modifications

    Activation of the IL1B precursor involves a CASP1-catalyzed proteolytic cleavage. Processing and secretion are temporarily associated.
  • Cellular localization

    Cytoplasm, cytosol. Lysosome. Secreted, exosome. Cytoplasmic vesicle, autophagosome. Secreted. The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome or bacterial flagellin for NLRC4 inflammasome, cleaved and secreted. IL1B lacks any known signal sequence and the pathway(s) of its secretion is(are) not yet fully understood (PubMed:24201029). On the basis of experimental results, several unconventional secretion mechanisms have been proposed. 1. Secretion via secretory lysosomes: a fraction of CASP1 and IL1B precursor may be incorporated, by a yet undefined mechanism, into secretory lysosomes that undergo Ca(2+)-dependent exocytosis with release of mature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes or multivesicular bodies (MVBs) and then merge with the plasma membrane releasing soluble IL1B or IL1B-containing exosomes (PubMed:24201029). However, autophagy impacts IL1B production at several levels and its role in secretion is still controversial. 3. Secretion via exosomes: ATP-activation of P2RX7 leads to the formation of MVBs containing exosomes with entrapped IL1B, CASP1 and other inflammasome components. These MVBs undergo exocytosis with the release of exosomes. The release of soluble IL1B occurs after the lysis of exosome membranes (By similarity). 4. Secretion by microvesicle shedding: activation of the ATP receptor P2RX7 may induce an immediate shedding of membrane-derived microvesicles containing IL1B and possibly inflammasome components. The cytokine is then released in the extracellular compartment after microvesicle lysis (PubMed:11728343). 5. Release by translocation through permeabilized plasma membrane. This may occur in cells undergoing pyroptosis due to sustained activation of the inflammasome (By similarity). These mechanisms may not be not mutually exclusive.
  • Information by UniProt
  • Database links

  • Alternative names

    • Catabolin antibody
    • H1 antibody
    • IFN beta inducing factor antibody
    • IL 1 antibody
    • IL 1 beta antibody
    • IL-1 beta antibody
    • IL1 antibody
    • IL1 BETA antibody
    • IL1B antibody
    • IL1B_HUMAN antibody
    • IL1F2 antibody
    • Interleukin 1 beta antibody
    • Interleukin 1 beta precursor antibody
    • interleukin 1, beta antibody
    • Interleukin-1 beta antibody
    • OAF antibody
    • Osteoclast activating factor antibody
    • OTTHUMP00000162031 antibody
    • Preinterleukin 1 beta antibody
    • Preinterleukin beta antibody
    • Pro interleukin 1 beta antibody
    see all

Images

  • IL-1 beta was immunoprecipitated from 0.35 mg THP-1 (human monocytic leukemia monocyte) whole cell lysate treated with 100 ng/ml lipopolysaccharide (LPS) for 3 hours, with ab216995 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab216995 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.


    Lane 1: THP-1 (human monocytic leukemia monocyte) treated with 100 ng/ml lipopolysaccharide (LPS) for 3 hours whole cell lysate 10 µg (Input).
    Lane 2: ab216995 IP in THP-1 treated with 100 ng/ml lipopolysaccharide (LPS) for 3 hours whole cell lysate (+).
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab216995 in THP-1 treated with 100 ng/ml lipopolysaccharide (LPS) for 3 hours whole cell lysate (-).
    Blocking and dilution buffer and concentration: 5% NFDM/TBST.
    Exposure time: 3 minutes.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab216995).

  • All lanes : Anti-IL-1 beta antibody [EPR21086] (ab216995) at 1/1000 dilution

    Lane 1 : Untreated THP-1 (human monocytic leukemia monocyte) whole cell lysate
    Lane 2 : THP-1 treated with 100 ng/ml Lipopolysaccharide (LPS) for 3 hours

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Developed using the ECL technique.

    Predicted band size: 30 kDa


    Exposure time: 3 minutes


    Blocking/Dilution buffer and concentration: 5% NFDM/TBST.

    The expression profile is consistent with the literature (PMID 15192144 and 10845914).

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab216995).

References

ab229696 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab229696.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up